MASH Treatment Market 2025

MASH Treatment Market Size

The global MASH treatment market reached a value of nearly $2,597.53 million in 2024, having grown at a compound annual growth rate (CAGR) of 21.55% since 2019. The market is expected to grow from $2,597.53 million in 2024 to $7,045.26 million in 2029 at a rate of 22.09%. The market is then expected to grow at a CAGR of 21.53% from 2029 and reach $18,679.22 million in 2034. Growth in the historic period resulted from the rising research and development (R&D) spending in life sciences, rising demand for personalized medicine, supportive government initiatives and growing awareness and screening programs. Factors that negatively affected growth in the historic period were stringent and complex regulatory requirements and limited awareness among general population. Going forward, growing interest in combination therapies, increasing incidence of non-alcoholic fatty liver disease (NAFLD), rising demand for liver transplants and growing prevalence of obesity will drive the growth. Factor that could hinder the growth of the MASH treatment market in the future include high cost of emerging treatments, limited biomarker availability and impact of trade war and tariffs.

MASH Treatment Market Drivers

The key drivers of the MASH treatment market include: Rising Demand For Liver Transplants Rising demand for liver transplants is expected to be a key driver of the growth of the MASH treatment market in the forecast period. As MASH progresses, it can lead to advanced fibrosis, cirrhosis and liver failure, making transplantation the only viable option for many patients. However, the shortage of donor livers, high costs and post-transplant complications have intensified the need for effective pharmacological interventions that can halt or reverse disease progression before transplantation becomes necessary. This urgency has spurred accelerated R&D in MASH therapeutics, with pharmaceutical companies focusing on anti-fibrotic, metabolic and anti-inflammatory drugs to prevent liver deterioration. Additionally, healthcare systems and insurers are increasingly incentivizing early treatment to reduce the long-term burden of transplant-related expenses. The rising demand for liver transplants growth contribution during the forecast period in 2024 is 0.50%.

MASH Treatment Market Restraints

The key restraints on the MASH treatment market include: High Cost Of Emerging Treatments High cost of emerging treatments is restricting the growth of the MASH treatment market during the forecast period. Novel MASH drugs, such as FXR agonists, THR-β modulators and combination therapies, often carry premium price tags due to extensive R&D investments, complex clinical trials and the need for long-term efficacy and safety data. Many healthcare systems, particularly in cost-sensitive markets, are hesitant to reimburse these expensive therapies without demonstrable long-term benefits (e.g., reduced liver transplants or mortality). The lack of cost-effective diagnostic tools for widespread screening means fewer patients are identified early, further limiting the eligible treatment pool. Growth affected by high cost of emerging treatments during the forecast period in 2024 is -1.95%.

MASH Treatment Market Trends

Major trends shaping the MASH treatment market include: Integration Of Artificial Intelligence (AI) In MASH Treatment Major companies operating in the MASH treatment market are focusing on integration of artificial intelligence (AI) in MASH treatment market to enhance precision in disease assessment and treatment outcomes. Companies are increasingly leveraging AI to support non-invasive, accurate evaluation of liver fibrosis, a key factor in MASH progression. For instance, in March 2025, HistoIndex, a Singapore based company engaged in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHT. FibroSIGHT seamlessly integrates into routine clinical workflows, leveraging on HistoIndex’s proprietary stain-free imaging technology to enhance the sensitivity of fibrillar collagens detection — key in evaluating fibrosis severity in liver biopsy samples. By eliminating variability associated with traditional staining techniques, FibroSIGHT delivers reliable and precise fibrosis assessment for MASH patients. Also, in February 2025, Insilico Medicine, a US based clinical-stage generative artificial intelligence (AI)-driven drug discovery company, achieved preclinical milestone in its collaboration with Therasid Bioscience, a South Korean based biotechnology company focuses on developing innovative first-in-class drugs for treatment for metabolic dysfunction-associated steatohepatitis (MASH). Insilico's team synthesized and tested approximately 40 molecules by leveraging its proprietary AI-powered generative chemistry engine, Chemistry42. Strategic Partnerships And Collaborations Among Market Players Companies in the MASH treatment market are adopting a strategic partnership approach for business expansion in the market. Strategic partnerships enable companies to leverage each other's strengths and resources to achieve mutual benefits and success. For example, in April 2024, Boehringer, a Germany-based pharmaceutical company actively involved in developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), entered a multi-year collaboration with Ochre Bio, a UK-based biotech, to develop RNA therapies targeting chronic liver diseases, with a primary focus on MASH. The deal includes $35 million upfront and potential milestones exceeding $1 billion. The partnership aim is to identify, characterize and validate multiple novel regenerative targets that could enhance the liver’s self-repair capabilities, potentially halting or reversing disease progression in MASH and other chronic liver diseases. Further, in January 2024, Suzhou Ribo Life Science Co., Ltd., a China-based clinical-stage company and Ribocure Pharmaceuticals AB (Ribo), a Sweden-based clinical-stage biotechnology company, announced a collaboration with Boehringer Ingelheim for $2 billion. This partnership aims to develop innovative treatments for nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH) by combining Ribo’s RNAi therapeutic platform with Boehringer Ingelheim’s expertise in cardiovascular, renal and metabolic diseases. The collaboration focuses on addressing the urgent need for effective therapies to halt NASH progression and restore liver function. Boehringer Ingelheim is a Germany-based pharmaceutical company actively involved in developing treatments for metabolic dysfunction-associated steatohepatitis (MASH).

Opportunities And Recommendations In The MASH Treatment Market

Opportunities – The top opportunities in the MASH treatment market segmented by treatment will arise in the drug segment, which will gain $3,674.70 million of global annual sales by 2029. The top opportunities in the MASH treatment market segmented by end-user will arise in the hospitals segment, which will gain $2,081.26 million of global annual sales by 2029. The top opportunities in the MASH treatment market segmented by disease stage will arise in the early MASH (significant/advanced fibrosis) segment, which will gain $2,098.32 million of global annual sales by 2029. The MASH treatment market size will gain the most in the USA at $1,689.67 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the MASH treatment market companies to Focus on Advancing FGF21-Based Therapies to Address MASH and Broader Liver Conditions, Focus on Integrating AI to Improve Diagnostic Accuracy and Drug Discovery in MASH, Focus on Drug Segment to Maximize Growth in MASH Treatment Market, Expand In Emerging Markets, Continue To Focus On Developed Markets, Provide Competitively Priced Offerings, Continue To Use B2B Promotions, Focus on Strategic Partnerships to Accelerate Innovation and Expand Market Reach, Focus on Specialty Clinics to Capture Highest-Growth End-User Segment.